Preventing clinically important deterioration with single-inhaler triple therapy in COPD

ERJ Open Research

Volumn 4, Issue 4, 2018, Pages

  Naya, Ian ^a   Compton, Chris ^a   Ismaila, Afisi S ^b,c   Birk, Ruby ^a   Brealey, Noushin ^a   Tabberer, Maggie ^a   Zhu, Chang Qing ^a   Lipson, David A ^d,e   Criner, Gerard ^f  

^a GLAXOSMITHKLINE   (United Kingdom)

^b NATIONAL INSTITUTES OF HEALTH   (United States)

^c MCMASTER UNIVERSITY   (Canada)

^d GLAXOSMITHKLINE   (United States)

^e UNIVERSITY OF PENNSYLVANIA   (United States)

^f TEMPLE UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BUDESONIDE; FLUTICASONE FUROATE; FORMOTEROL; PLACEBO; UMECLIDINIUM; VILANTEROL;

ADULT; AIRWAY OBSTRUCTION; ARTICLE; CARDIOVASCULAR RISK; CHRONIC OBSTRUCTIVE LUNG DISEASE; CONTROLLED STUDY; DETERIORATION; DISEASE EXACERBATION; DOUBLE BLIND PROCEDURE; FEMALE; FORCED EXPIRATORY VOLUME; HOSPITALIZATION; HUMAN; INCIDENCE; LUNG FUNCTION; MALE; MIDDLE AGED; MULTICENTER STUDY; PRACTICE GUIDELINE; RANDOMIZED CONTROLLED TRIAL; RISK ASSESSMENT; SENSITIVITY ANALYSIS; SMOKING; SPIROMETRY; ST. GEORGE RESPIRATORY QUESTIONNAIRE;

EID: 85067619733     PISSN: None     EISSN: 23120541     Source Type: Journal    
DOI: 10.1183/23120541.00047-2018     Document Type: Article

References (22)

1. Global Initiative for Chronic Obstructive Lung Disease (GOLD). GOLD Global Strategy for the Diagnosis, Management and Prevention of COPD. 2017. http://goldcopd.org/gold-2017-global-strategy-diagnosis-management-prevention-copd/Date last accessed: October 10, 2017.
2. Aaron SD, Vandemheen KL, Fergusson D, et al. Tiotropium in combination with placebo, salmeterol, or fluticasone-salmeterol for treatment of chronic obstructive pulmonary disease: a randomized trial. Ann Intern Med 2007; 146: 545–555.
3. Welte T, Miravitlles M, Hernandez P, et al. Efficacy and tolerability of budesonide/formoterol added to tiotropium in patients with chronic obstructive pulmonary disease. Am J Respir Crit Care Med 2009; 180: 741–750.
4. 2-agonists for patients with COPD: pooled results of randomized placebo-controlled trials. Pulm Ther 2016; 2: 43–58.
5. 2-agonist therapy for chronic obstructive pulmonary disease (TRILOGY): a double-blind, parallel group, randomised controlled trial. Lancet 2016; 388: 963–973.
6. Vestbo J, Papi A, Corradi M, et al. Single inhaler extrafine triple therapy versus long-acting muscarinic antagonist therapy for chronic obstructive pulmonary disease (TRINITY): a double-blind, parallel group, randomised controlled trial. Lancet 2017; 389: 1919–1929.
7. Lipson DA, Barnacle H, Birk R, et al. FULFIL trial: once-daily triple therapy for patients with chronic obstructive pulmonary disease. Am J Respir Crit Care Med 2017; 196: 438–446.
8. Singh D, Maleki-Yazdi MR, Tombs L, et al. Prevention of clinically important deteriorations in COPD with umeclidinium/vilanterol. Int J Chron Obstruct Pulmon Dis 2016; 11: 1413–1424.
9. Maleki-Yazdi MR, Singh D, Anzueto A, et al. Assessing short-term deterioration in maintenance-naïve patients with COPD receiving umeclidinium/vilanterol and tiotropium: a pooled analysis of three randomized trials. Adv Ther 2017; 33: 2188–2199.
10. Anzueto AR, Vogelmeier CF, Kostikas K, et al. The effect of indacaterol/glycopyrronium versus tiotropium or salmeterol/fluticasone on the prevention of clinically important deterioration in COPD. Int J Chron Obstruct Pulmon Dis 2017; 12: 1325–1337.
11. Jones PW, Harding G, Berry P, et al. Development and first validation of the COPD Assessment Test. Eur Respir J 2009; 34: 648–654.
12. Jones PW, Harding G, Wiklund I, et al. Tests of the responsiveness of the COPD assessment test following acute exacerbation and pulmonary rehabilitation. Chest 2012; 142: 134–140.
13. Miller MR, Hankinson J, Brusasco V, et al. Standardisation of spirometry. Eur Respir J 2005; 26: 319–338.
14. Naya IP, Lipson DA, Compton C. Prevention of early worsening of COPD with umeclidinium open triple therapy compared with inhaled corticosteroid/long-acting β2-agonist alone: a pooled post hoc analysis. Am J Respir Crit Care Med 2017; 195: A3608.
15. Naya IP, Tombs L, Jones P. Short-term clinically important deterioration predicts long-term clinical outcome in COPD patients: a post-hoc analysis of the TORCH trial. Thorax 2015; 70: Suppl. 3, A34.
16. Naya IP, Driessen MT, Paly V, et al. Long-term consequences of clinically important deterioration in patients with chronic obstructive pulmonary disease treated with twice-daily inhaled corticosteroid/long-acting β2-agonist therapy: results from the TORCH study. Am J Respir Crit Care Med 2018; 197: A3042.
17. Naya IP, Tombs L, Mullerova H, et al. Long-term outcome following first clinically important deterioration in COPD. Eur Respir J 2016; 48: PA304.
18. Rabe KF, Halpin D, Martinez F, et al. Predicting long-term outcomes and future deterioration in COPD with a composite endpoint: post hoc analysis of the UPLIFT study. Am J Respir Crit Care Med 2017; 195: A2717.
19. Rabe KF, Halpin D, Martinez F, et al. Relative timing of clinically important deterioration and related long-term outcomes in COPD: a post hoc analysis of the UPLIFT study. Pneumologie 2018; 72: S86–S87.
20. Wilke S, Jones PW, Müllerova H, et al. One-year change in health status and subsequent outcomes in COPD. Thorax 2015; 70: 420–425.
21. So JY, Lastra AC, Zhao H, et al. Daily peak expiratory flow rate and disease instability in chronic obstructive pulmonary disease. Chronic Obstr Pulm Dis 2015; 3: 398–405.
22. Pascoe SJ, Lipson DA, Locantore N, et al. A phase III randomised controlled trial of single-dose triple therapy in COPD: the IMPACT protocol. Eur Respir J 2016; 48: 320–330.